About “Kadcyla”, Ado-trastuzumab emtansine and HER2-Amplified Advanced Salivary Gland Cancer, SGC - Ado-trastuzumab emtansine, more commonly known as T-DM1 and sold under the trade name “Kadcyla”, is a HER2 targeted antibody-drug…
Background Researchers from Baylor College of Medicine published preliminary findings on the first two patients treated in a Phase I clinical trial, first of its kind in humans, with innovative…
CAR-T against HER2 in advanced Sarcomas The International AACR conference was recently held in the US. The results of a Phase I study were presented in 10 patients with advanced…
Nerlynx in metastatic cervical cancer About a week ago, preliminary results were published in a study examining the efficacy and safety of aN approved drug, called Nerlynx. The study involved…
About A.G. A.G. turned to us about two months ago and told us that her doctor, from a large medical center in the center of the country, was pressing her…
What did Cabometix® demonstrate? Two drugs, Cabometix® (Cabozantinib) and Stivarga® (Regorafenib) are approved for various indications and are now breakthroughs in the treatment of advanced stages of these two types…